new pharmacy info:
Herbal Phentermine, Anatrim Diet Pills, Acomplia, Zimulti, Rimonabant, Hoodia, Yerba Diet, Superloss Multi, Green tea, CLA, Chitosan, Diet Maxx, AyurSlim, Hoodia Weight Loss Gum, Hoodia Weight Loss Patch, Premium Diet Patch
понедельник, 12 мая 2008 г.
Two-Year Outcome of a Combination of Weight Loss Therapies for Type 2 Diabetes
Objective: To evaluate the effects over 2 years of a weight loss program combining several weight loss strategies on weight loss and diabetes control in overweight subjects with type 2 diabetes.Research Design and Methods: A total of 59 overweight or obese individuals with type 2 diabetes were randomly assigned to either a combination therapy weight loss program for 2 years (C therapy) or a standard therapy weight loss program for 1 year followed by a combination therapy weight loss program in the 2nd year (S/C therapy). C therapy combined the use of meal replacement products, repetitive intermittent low-calorie-diet weeks, and pharmacologic therapy with sibutramine. Outcome measures included changes in weight, glycemic control, plasma lipids, blood pressure, and body composition over 2 years.Results: A total of 48 participants (23 in the C therapy group and 25 in the S/C therapy group) completed 2 years of study. After 2 years, the C therapy group had weight loss of 4.6 ± 1.2 kg ( P < 0.001) and a decrease in HbA1c of 0.5 ± 0.3% ( P = 0.08) from baseline. At 2 years, the C therapy group had significant reductions in BMI, fat mass, lean body mass, and systolic blood pressure. The S/C therapy group showed changes in weight and HbA1c in year 2 of the study that were similar to those demonstrated by the C therapy group in year 1.Conclusions: This combination weight loss program resulted in significant weight loss and improved diabetes control over a 2-year period in overweight subjects with type 2 diabetes.
Introduction
Weight loss is an important therapeutic objective for individuals with type 2 diabetes.[1] Short-term studies have demonstrated that weight loss in overweight or obese type 2 diabetic subjects is associated with decreased insulin resistance, improved measures of glycemic control, reduced lipemia, and reduced blood pressure.[2-4] However, the most recent American Diabetes Association nutrition recommendations concluded that "optimal strategies for preventing and treating obesity long term have yet to be defined".[5]
Long-term options to promote weight loss in people with type 2 diabetes include standard weight-reduction diets and very-low-calorie diets. However, standard weight-reduction diets are usually not effective.[5] Very-low-calorie diets produce substantial initial weight loss but do not maintain weight loss long term.[6]
Other approaches to weight loss that might be effective in type 2 diabetic subjects include use of meal replacements, repetitive use of low-calorie diets, and weight loss medications. Hensrud[7] reported significant weight loss at 3 months using meal replacements in type 2 diabetic subjects, but weight and measures of glycemic control trended toward baseline values at 1 year. Williams et al.[8] compared a standard diet to very-low-calorie diets used either 1 day per week or 5 consecutive days every 5 weeks in type 2 diabetic subjects. After 15 weeks, the very-low-calorie diet groups lost 9.6 and 10.4 kg, respectively, compared with weight loss of 5.4 kg in the standard diet group, but longer-term follow-up was not provided. Sibutramine treatment of type 2 diabetic subjects for 6 months produced weight loss of ~4.5% but had only modest effects on HbA1c in two studies[9,10] and, at a dose of 15 mg daily, produced weight loss of 5.5 kg and a decrement in HbA1c of 0.6% at 1 year in another study.[11] Three 1-year trials compared orlistat to placebo in type 2 diabetic subjects.[12-14] Weight loss at 1 year ranged from 4 to 6%, and decrements in HbA1c ranged from 0.5 to 0.9%.
With these studies in mind, we hypothesized that efficacy might be increased if several weight loss approaches were combined. Accordingly, we initiated a clinical trial combining intermittent low-calorie diets, energy-controlled meal replacements, and sibutramine to treat overweight and obese type 2 diabetic subjects. The 1-year results have previously been reported.[15] Herein, we report the 2-year results with primary focus on those subjects who received the combination therapy weight loss program throughout the entire 2 years of study.
Introduction
Weight loss is an important therapeutic objective for individuals with type 2 diabetes.[1] Short-term studies have demonstrated that weight loss in overweight or obese type 2 diabetic subjects is associated with decreased insulin resistance, improved measures of glycemic control, reduced lipemia, and reduced blood pressure.[2-4] However, the most recent American Diabetes Association nutrition recommendations concluded that "optimal strategies for preventing and treating obesity long term have yet to be defined".[5]
Long-term options to promote weight loss in people with type 2 diabetes include standard weight-reduction diets and very-low-calorie diets. However, standard weight-reduction diets are usually not effective.[5] Very-low-calorie diets produce substantial initial weight loss but do not maintain weight loss long term.[6]
Other approaches to weight loss that might be effective in type 2 diabetic subjects include use of meal replacements, repetitive use of low-calorie diets, and weight loss medications. Hensrud[7] reported significant weight loss at 3 months using meal replacements in type 2 diabetic subjects, but weight and measures of glycemic control trended toward baseline values at 1 year. Williams et al.[8] compared a standard diet to very-low-calorie diets used either 1 day per week or 5 consecutive days every 5 weeks in type 2 diabetic subjects. After 15 weeks, the very-low-calorie diet groups lost 9.6 and 10.4 kg, respectively, compared with weight loss of 5.4 kg in the standard diet group, but longer-term follow-up was not provided. Sibutramine treatment of type 2 diabetic subjects for 6 months produced weight loss of ~4.5% but had only modest effects on HbA1c in two studies[9,10] and, at a dose of 15 mg daily, produced weight loss of 5.5 kg and a decrement in HbA1c of 0.6% at 1 year in another study.[11] Three 1-year trials compared orlistat to placebo in type 2 diabetic subjects.[12-14] Weight loss at 1 year ranged from 4 to 6%, and decrements in HbA1c ranged from 0.5 to 0.9%.
With these studies in mind, we hypothesized that efficacy might be increased if several weight loss approaches were combined. Accordingly, we initiated a clinical trial combining intermittent low-calorie diets, energy-controlled meal replacements, and sibutramine to treat overweight and obese type 2 diabetic subjects. The 1-year results have previously been reported.[15] Herein, we report the 2-year results with primary focus on those subjects who received the combination therapy weight loss program throughout the entire 2 years of study.
Подписаться на:
Сообщения (Atom)
